ASCO 2014

asco xAmerican Society of Clinical Oncology (ASCO)
2014 Annual Meeting

May 30 - June 3, 2014

McCormick Place
Chicago, IL USA

#ASCO14 - Poster: Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin DF,1 Gomella LG,2 Sharma P,3 Plimack ER,4 O’Donnell PH,5 Hoffman-Censits J,2 Flaig TW,6 Quinn DI,7 Campogan D,8 Haynes H,8 McCoy C,8 Maher J,8 DeVries T,8 Sheikh N,8 and Lerner SP9 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Activity of abiraterone acetate in metastatic castration-resistant prostate cancer patients previously treated with ketoconazole: A prospective phase II study from the Prostate Cancer Clinical Trials Consortium

CHICAGO, IL USA (UroToday.com) - Presented by Won Kim, John Wilton, Li Zhang, Amy M. Lin, Lawrence Fong, Andrew Caleb Hsieh, Terence W. Friedlander, Rahul Raj Aggarwal, Vivian K. Weinberg, Allison Morse, Jeffrey Bozeman, Arturo Molina, Gerald J. Fetterly, James Mohler, Russell Zelig Szmulewitz, Eric Jay Small, and Charles J. Ryan at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - The site of visceral metastases to predict overall survival in castration-resistant prostate cancer (CRPC) patients: A meta-analysis of five phase III trials - Session Highlights

CHICAGO, IL USA (UroToday.com) - Several previous studies, as well as clinical practice, suggest that the site of metastatic disease influences overall survival among men with metastatic castrate resistant prostate cancer (CRPC).

#ASCO14 - Final results of EORTC intergroup randomized phase III trial comparing immediate vs deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder - Session Highlights

CHICAGO, IL USA (UroToday.com) - This study is an update on an EORTC intergroup phase III randomized controlled clinical trial of the effectiveness of immediate adjuvant chemotherapy, when used in patients with muscle-invasive bladder cancer, treated with radical cystectomy.

#ASCO14 - Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011) - Session Highlights

CHICAGO, IL USA (UroToday.com) - Advances in treatment have improved survival outcomes among men with metastatic testicular germ cell tumors (TGCTs).

#ASCO14 - Poster: Establishing a neo-adjuvant platform for developing targeted agents: Androgen deprivation therapy prior to prostatectomy for patients with intermediate- and high-risk prostate cancer

CHICAGO, IL USA (UroToday.com) - Presented by K. A. Touijer, Y. Chen, B. S. Carver, J. A. Coleman, V. P. Laudone, M. Hullings, S. S. Ehrlich, M. DeNunzio, V. E. Reuter, J. A. Eastham, D. C. Danila, S. F. Slovin, M. J. Morris, Y. Chen, P. T. Scardino, H. I. Scher, and D. E. Rathkopf at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action

CHICAGO, IL USA (UroToday.com) - Presented by Stefanie J. Mandl, Ryan B. Rountree, Rachel E. Owen, Tracy dela Cruz, Olivia Hwang, Gayatri Paranjpe, Amanda Enstrom, Alex Franzusoff, Carsten Goessl, and James B. Breitmeyer  at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Page 1 of 5